Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.

Article  PubMed  Google Scholar 

Pliarchopoulou K, Pectasides D. Epithelial ovarian cancer: focus on targeted therapy. Crit Rev Oncol Hematol. 2011;79(1):17–23.

Article  PubMed  Google Scholar 

Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kozlowski M, Nowak K, Cymbaluk-Ploska A. Long-term follow-up of a female patient treated with olaparib-hope for a long life without relapse? Int J Environ Res Public Health. 2021;18:7.

Article  Google Scholar 

Zamwar UM, Anjankar AP. Aetiology, epidemiology, histopathology, classification, detailed evaluation, and treatment of ovarian cancer. Cureus. 2022;14(10): e30561.

PubMed  PubMed Central  Google Scholar 

Song Z, Zhou Y, Bai X, Zhang D. A practical nomogram to predict early death in advanced epithelial ovarian cancer. Front Oncol. 2021;11: 655826.

Article  PubMed  PubMed Central  Google Scholar 

Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284–96.

Article  PubMed  PubMed Central  Google Scholar 

Zhou S, Liu Y, Yin W, Liao Q, Quan Q, Mu X. Clinicopathologic factors associated with short-term survival in advanced epithelial ovarian cancer. Transl Cancer Res. 2019;8(6):2396–404.

Article  PubMed  PubMed Central  Google Scholar 

De Leo A, Santini D, Ceccarelli C, Santandrea G, Palicelli A, Acquaviva G, Chiarucci F, Rosini F, Ravegnini G, Pession A, Turchetti D, Zamagni C, Perrone AM, De Iaco P, Tallini G, de Biase D. What is new on ovarian carcinoma: integrated morphologic and molecular analysis following the new 2020 world health organization classification of female genital tumors. Diagnostics. 2021;11:4.

Google Scholar 

Fostira F, Papadimitriou M, Papadimitriou C. Current practices on genetic testing in ovarian cancer. Ann Transl Med. 2020;8(24):1703.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kwiatkowski F, Arbre M, Bidet Y, Laquet C, Uhrhammer N, Bignon YJ. BRCA mutations increase fertility in families at hereditary breast/ovarian cancer risk. PLoS ONE. 2015;10(6): e0127363.

Article  PubMed  PubMed Central  Google Scholar 

Kim D, Nam HJ. PARP inhibitors: clinical limitations and recent attempts to overcome them. Int J Mol Sci. 2022;23:15.

Google Scholar 

Zhou P, Wang J, Mishail D, Wang CY. Recent advancements in PARP inhibitors-based targeted cancer therapy. Precis Clin Med. 2020;3(3):187–201.

Article  PubMed  PubMed Central  Google Scholar 

Toma M, Skorski T, Sliwinski T. DNA double strand break repair - related synthetic lethality. Curr Med Chem. 2019;26(8):1446–82.

Article  CAS  PubMed  Google Scholar 

Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci. 2004;95(11):866–71.

Article  CAS  PubMed  Google Scholar 

Goff BA. Advanced ovarian cancer: what should be the standard of care? J Gynecol Oncol. 2013;24(1):83–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hockings H, Miller RE. The role of PARP inhibitor combination therapy in ovarian cancer. Ther Adv Med Oncol. 2023;15:17588359231173184.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Leung D, Price ZK, Lokman NA, Wang W, Goonetilleke L, Kadife E, Oehler MK, Ricciardelli C, Kannourakis G, Ahmed N. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism. J Transl Med. 2022;20(1):556.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yusoh NA, Ahmad H, Gill MR. Combining PARP inhibition with platinum, ruthenium or gold complexes for cancer therapy. ChemMedChem. 2020;15(22):2121–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin ZP, Zhu YL, Lo YC, Moscarelli J, Xiong A, Korayem Y, Huang PH, Giri S, LoRusso P, Ratner ES. Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer. PLoS ONE. 2018;13(11): e0207399.

Article  PubMed  PubMed Central  Google Scholar 

Gilad Y, Gellerman G, Lonard DM, O’Malley BW. Drug combination in cancer treatment-from cocktails to conjugated combinations. Cancers. 2021;13:4.

Article  Google Scholar 

Mayer LD, Janoff AS. Optimizing combination chemotherapy by controlling drug ratios. Mol Interv. 2007;7(4):216–23.

Article  CAS  PubMed  Google Scholar 

Shah V, Taratula O, Garbuzenko OB, Taratula OR, Rodriguez-Rodriguez L, Minko T. Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug. Clin Cancer Res. 2013;19(22):6193–204.

Article  CAS  PubMed  Google Scholar 

Sapiezynski J, Taratula O, Rodriguez-Rodriguez L, Minko T. Precision targeted therapy of ovarian cancer. J Control Release. 2016;243:250–68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dharap SS, Wang Y, Chandna P, Khandare JJ, Qiu B, Gunaseelan S, Sinko PJ, Stein S, Farmanfarmaian A, Minko T. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc Natl Acad Sci U S A. 2005;102(36):12962–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nsairat H, Khater D, Sayed U, Odeh F, Al Bawab A, Alshaer W. Liposomes: structure, composition, types, and clinical applications. Heliyon. 2022;8(5): e09394.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maja L, Željko K, Mateja P. Sustainable technologies for liposome preparation. J Supercritic Fluids. 2020;165: 104984.

Article  CAS  Google Scholar 

Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, Diaz-Torres LA, Grillo R, Swamy MK, Sharma S, Habtemariam S, Shin HS. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol. 2018;16(1):71.

Article  Google Scholar 

Zhang M, Garbuzenko OB, Reuhl KR, Rodriguez-Rodriguez L, Minko T. Two-in-one: combined targeted chemo and gene therapy for tumor suppression and prevention of metastases. Nanomedicine (Lond). 2012;7(2):185–97.

Article  CAS  PubMed  Google Scholar 

Ford CE, Werner B, Hacker NF, Warton K. The untapped potential of ascites in ovarian cancer research and treatment. Br J Cancer. 2020;123(1):9–16.

Article  PubMed  PubMed Central  Google Scholar 

Skupin-Mrugalska P, Minko T. Development of liposomal vesicles for osimertinib Delivery to EGFR mutation-positive lung cancer cells. Pharmaceutics. 2020;12:10.

Article  Google Scholar 

Zhang Y, Huo M, Zhou J, Zou A, Li W, Yao C, Xie S. DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. AAPS J. 2010;12(3):263–71.

Article  PubMed  PubMed Central